Medicare Definitions Of ‘Bona Fide Marketing,’ And ‘Single-Source Drug’ May Be Inconsistent With Law, Appeals Court Says

An appeals court panel seemed skeptical of whether AstraZeneca has standing in its Administrative Procedure Act challenges against the IRA’s drug price negotiation program, but suggested a company with standing might be successful in their court.